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Background: Peripheral inflammation leads to the development of persistent thermal
hyperalgesia and mechanical allodynia associated with increased expression of interleukin1β (IL-1β) in the spinal cord. The aim of the present study was to investigate the effects of
thiazolidine derivatives, 1b ([2-(2-hydroxyphenyl)-1,3-thiazolidin-4-yl](morpholin-4-yl)
methanone) and 1d (2-hydroxy-4-{[2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]
amino}benzoic acid), on thermal hyperalgesia, mechanical allodynia and on IL-1β expres
sion during carrageenan-induced inflammation in the spinal cord in mice. Inflammatory pain
was induced by injecting 1% carrageenan into the right hind paw of the mice.
Methods: The animals were administered thiazolidine derivatives, 1b and 1d (1 mg/kg, 3
mg/kg, or 10 mg/kg), intraperitoneally 30 minutes before carrageenan administration. The
animals’ behavior was evaluated by measuring thermal hyperalgesia, mechanical allodynia,
and motor coordination. The IL-1β expression was measured by enzyme-linked immunosor
bent assay. Acute and sub-acute toxicity studies were conducted to evaluate the toxicity
profile of compounds.
Results: Treatment with the thiazolidine derivative, 1b and 1d, attenuated carrageenaninduced thermal hyperalgesia and mechanical allodynia at doses of 1 mg/kg, 3 mg/kg, and
10 mg/kg. No motor coordination deficits were observed in animals. The compounds also
reduced IL-1β expression in the spinal cord of mice. Acute and sub-acute toxicity studies
revealed that both compounds were safe.
Conclusion: The compounds exhibit promising activity against inflammatory pain due to
their ability to produce anti-hyperalgesic and anti-allodynic effects and to inhibit IL-1β
expression in the spinal cord.
Keywords: inflammatory pain, IL-1β, thiazolidine derivatives, mechanical allodynia,
thermal hyperalgesia
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Pain is an essential adaptive response for the protection of the integrity of organism
and arises in response to actual or potential tissue-damaging stimuli. In some
instances, the component of pain persists despite the resolution of the inflammatory
injury state.1 Animal models with chronic inflammatory states have demonstrated
persistent allodynia (enhanced sensitivity to normally innocuous stimuli) and
hyperalgesia (increased sensitivity of painful stimuli).2 Similarly, a substantial
percentage of human patients have also shown an inability to resolve their pain
after the resolution of the injury.3,4 As pathology of pain is highly variable and
remains largely unresolved by currently available therapeutics, therefore there is a
need to explore novel targets for the pain control. Production and the release of
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proinflammatory cytokines in the spinal cord has been
recognized as an important mechanism in the induction
and maintenance of pathological pain states in the animal
models of pain.5,6 Targeting pro-inflammatory products
including IL-1β for the treatment of pain is becoming
widely recognized but it is still in infancy regarding poten
tial drug targets identification for pain.
Interleukin-1β (IL-1β) a key pro-inflammatory cyto
kine is the principal species of the interleukin-1 (IL-1)
family and is involved in the development, maintenance,
and propagation of pain sensitivity.7 IL-1β can be released
from microglia, neuronal cells or astrocytes in the central
nervous system (CNS), and produces additional allogenic
substances.7,8 It is found that in inflammatory pain
increased production of inflammatory mediators like IL1β occurs, which acts on nociceptive neurons and produce
hyperalgesia.9,10 Inhibitors of mediators such as interleu
kin-1β (Il-1β) have shown remarkable analgesic effects.
Pain associated behaviors in a mouse model of neuropathy
are reduced in response to neutralizing antibodies to IL-1β
receptors.11,12 Furthermore, thiazolidine derivatives have
been found to exhibit very prominent anti-inflammatory
and anti-nociceptive activity.13
Thiazolidine is an important scaffold and has a wide
range of promising biological activities. Thiazolidine deri
vatives have reported anti-inflammatory and anti-nocicep
tive activity.14 In a similar study, thiazolidine derivatives
exhibited promising anti-inflammatory and anti-nocicep
tive activity related to their ability to inhibit IL-1β
production.15 Various studies have reported that IL-1β
production in the spinal cord is also increased in chronic
pain similar to the increased IL-1β production in inflam
matory pain.16–18 However, in this study our emphasis will
be mainly on inflammatory pain. Therefore, the present
study was designed to evaluate possible beneficial effects
of synthetic thiazolidine derivatives such as 1b, ([2-(2hydroxyphenyl)-1,3-thiazolidin-4-yl](morpholin-4-yl)
methanone and 1d, (2-hydroxy-4-{[2-(2-hydroxyphenyl)1,3-thiazolidine-4-carbonyl]aminobenzoic acid), shown in
Figures 1A and B against carrageenan-induced hyperalge
sia to thermal stimuli and mechanical allodynia. Usually,
the endogenous antioxidant system keeps oxidative stress
under control. However, oxidative stress increases during
inflammatory processes at a rate which overcomes the
capability of endogenous antioxidants to counter it. The
resulting imbalance causes the oxidative stress productmediated injury and which results in the enhancement of
pain.19,20 It has also been reported that there is a very
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Figure 1 Structure of the thiazolidine derivatives; (A) (1b) [2-(2-hydroxyphenyl)1,3-thiazolidin-4-yl](morpholin-4-yl)methanone, (B) (1d) 2-hydroxy-4-{[2-(2-hydro
xyphenyl)-1,3-thiazolidine-4-carbonyl]amino}benzoic acid.

strong correlation between the oxidative stress and pain.21
The antioxidant potential of the thiazolidine compounds is
also evaluated. We also investigated the effects of thiazo
lidine derivatives on IL-1β production in the spinal cord of
an animal model. To evaluate the safety profile, acute and
sub-acute toxicity studies of the compounds were also
performed.

Materials and Methods
Animals
Adult male and female Balb-C mice weighing between
20–30 g were obtained from the animal house of Riphah
Institute of Pharmaceutical Sciences (RIPS). Mice were
divided into male and female groups (n=6). Mice were
housed four-to-five per cage in temperature and humiditycontrolled (22°C±2, the relative humidity of between 50
and 60%) environment. A 12-hour of light and dark cycle
was maintained and open access to water and food was
provided to mice. Riphah Institute of Pharmaceutical
Sciences Ethical Committee, Pakistan approved all the
procedures prior to performing (Ref No. REC/RIPS/
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2018/01). The guidelines of the Animals scientific proce
dures Act (1986) were followed which are in line with the
guidelines of the Animal Welfare Act, 2009.
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maximum of 30 seconds cut-off time was used to prevent
tissue damage.27

Measurement of Mechanical Allodynia
Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 13.52.65.12 on 18-Mar-2021
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Chemicals
All the doses of the compounds were calculated based on
the weight of the animals. The synthetic thiazolidine com
pounds, 1b, and 1d, were gifted by the laboratory of
Pharmaceutical Chemistry Department, RIPS, Islamabad.
Pakistan. 5% Ethanol in saline was used as a vehicle for
compound 1b and 3% DMSO and 1.5% tween-80 in saline
was used as a vehicle for compound 1d. Rosiglitazone was
obtained from Werrick pharmaceuticals through a proper
channel and solution was prepared in normal saline.
Diazepam was obtained from the market through the
proper channel. Kappa-carrageenan was acquired from
Sigma-Aldrich. Solution of carrageenan was prepared in
normal saline.

Induction of Inflammatory Pain and Drug
Administration
Acute inflammatory pain was induced by injecting 20 µL
of 1% carrageenan into the plantar surface of the right hind
paw 30 minutes after intraperitoneal (IP) injection of thia
zolidine derivatives.22–24 Control group animals were
given vehicle (10 mL/kg) only. Thirty minutes before the
carrageenan injection each group of animals was given IP
injections of 1b or 1d (1, 3, or 10 mg/kg). Negative control
group animals were given a same volume of vehicle (5%
ethanol in the case of 1b and 3% DMSO and 1.5% Tween80 in the case of 1d). Positive control group animals
received rosiglitazone 30 minutes before carrageenan
injection. Behavioral assays (thermal hyperalgesia and
mechanical allodynia) were carried out blindly before the
injection of drug (naïve baseline), and then at intervals of
every 30 minutes (30, 60, 90, 120, 150, minutes) after
carrageenan injection. Each animal was tested three times
for single recording with a 5 seconds interval between the
two measurements to nullify the previous effect.22

Thermal Hyperalgesia
Increased sensitivity to thermal stimulus was measured by
hot plate test maintained at 55ºC±2.25,26 The animal were
briefly positioned on the hot plate in a plexiglass chamber
one by one. By using a stopwatch, paw withdrawal latency
was measured. The licking of the paw, flicking, or jumping
of the animal was noted as a positive response. A

Drug Design, Development and Therapy 2021:15

Mechanical allodynia was measured according to the
method described previously.28,29 Briefly, the mice after
placement in a plexiglass cage with mesh metal flooring
were acclimated to the environment for 30±5 minutes Von
Frey filaments of 0.16, 0.4, 0.6, 1, 1.4, and 2 g were
applied perpendicularly at the paw of mice using up and
down method. Each filament was used with a force that
caused slight bending and was held at same force for 2–3
seconds. The filament of 0.16 g was applied as a starting
filament to the paw of the mice kept in mesh metal floor
ing. In the nonexistence of the withdrawal response of the
paw to the initially selected lighter filament, a higher force
filament matching to a stronger stimulus was applied. In
the event of withdrawal response of paw, the next filament
of lighter force was selected. The same procedure was
repeated for consecutive five readings and the average
value of five scores was calculated.30,31 A 2 g force was
selected as cut-off force.

Rota Rod Test
To verify a possible effect of 1b and 1d on motor coordina
tion in mice, a Rota Rod Test was used.32 The apparatus
consisted of a horizontal bar with a diameter of 5 cm, sub
divided into four compartments. The mice were placed on the
bar rotating at a speed of 4 rpm and mice that were able to
remain on the rod longer than 60 seconds were selected 24
hours before test. The animals were treated with two doses of
3 mg/kg and 10 mg/kg of compound 1b and 1d, and vehicle
(10 mL/kg) or diazepam (2.0 mg/kg, IP). After 30 minutes
following the administration of 1b and 1d, each animal was
tested on the rotarod and the time of permanence (s) on the
bar during a 1 minute period was registered before (0 hour), 1
and 3 hours after drug administration.

Enzyme-Linked Immunosorbent Assay
(ELISA)
IL-1β expression in the spinal cord of mice was measured
by ELISA.13 At the end of the behavioral study experi
ment, the animals were sacrificed and their spinal cords
were extracted. Until analysis, their spinal cord tissues
were kept at −80ºC. On the experiment day, tissues were
homogenized in phosphate buffer saline (PBS) containing
5% tween-20 by probe sonicator.33 After homogenization
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the mixture was subjected to centrifugation at 8,500×g for
30 minutes at 4°C. After centrifugation, supernatants were
collected. The mouse ELISA kit (E-EL-M0037) for IL-1β
was employed to quantify IL-1β as per instructions pro
vided by manufacturer.

Antioxidant Activity by DPPH Radical
Scavenging Assay
Serial dilutions of compound 1b were prepared having
concentration of 1, 3, 10, 100, 300, 700, and 1,000 μg/
mL in 5% ethanol. Similarly, serial dilutions of 1d were
prepared with a concentration of 1, 3, 10, 100, 700, and
1000 μg/mL in 3% DMSO and 1.5% Tween-80. Then 3
mL of freshly prepared 1 mM DPPH prepared in methanol
was added to each of the concentrations of tested com
pounds. After shaking, to complete the reaction, the mix
ture was allowed to stand in the dark for 30 minutes. A
UV spectrophotometer was used to measure the absor
bance of the solution at 517 nm. The percentage of sample
to inhibit DPPH was calculated by the following formula.
�
�
ABS control ABS sample
% Inhibition ¼
%100
ABS control
A concentration (μM) against % inhibition of DPPH
graph was constructed. The concentration at which there
was a 50% fall in the absorbance of DPPH solution was
calculated from the graph (IC50). All the experiments were
performed in triplicate. For negative control the same
experiment was performed without test compounds.
Ascorbic acid was used as a standard (Positive
control).34,35

Determination of Acute and Sub-Acute
Toxicity in the Animal Model
For acute toxicity, male and female mice (n=3 each) were
divided into three groups. Group 1 received vehicle, group
2 received 1b (1,000 mg/kg), whereas group 3 received 1d
(1,000 mg/kg). The animals were then observed for the
next 24 hours for their behavior and mortality.36,37 For
sub-acute toxicity male and female mice (n=3 each) were
divided into three groups. Group 1 received IP dose of
vehicles after every 24 hours for consecutive 14 days.38
Groups 2 and 3 were administered 500 mg of 1b and 1d
intraperitoneally every 24 hours for consecutive 14 days.
Blood samples were withdrawn first after 24 hours of first
dose of the compounds and then at the 14th day of admin
istration of compounds. The blood was collected into non-
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heparinized tubes and centrifuged at 3,000 rpm for 10
minutes. The serum was separated and stored for biochem
ical analysis. Serum biochemical analysis was performed
for alkaline-phosphatase (ALP), aspartate-aminotransfer
ase (AST), alanine-aminotransferase (ALT), and
creatinine.39

Statistical Analysis
The Graph Pad Prism 6.0 (Graph-Pad, San Diego, CA)
was used to analyze the data. Behavioral data was exam
ined by using two-way ANOVA (two-way analysis of
variance) followed by Tukey’s post hoc test. For biochem
ical data, one way-ANOVA followed by Tukey’s post hoc
test was applied. Data were demonstrated as mean±SEM.
Significant statistical differences were at *P<0.05;
**P<0.01; ***P<0.001.

Results
Effect of Thiazolidine Derivatives on
Carrageenan-Induced Thermal
Hyperalgesia in Male Mice
Adult male mice (n=6/each group) were given an intraplantar injection of carrageenan (1%) and then tested
for hyperalgesia at 30, 60, 90, 120, and at 150 minute
intervals. After 30 minutes of carrageenan injection
reduction in mean withdraw latencies of paw in the
negative control group was significant, 7±1.07 s
(*P<0.05) as compared to the saline given to the nor
mal control group (11.5±0.4 s, n=6) (Figure 2A and B).
Administration of the compound 1b and 1d 30 minutes
before the carrageenan injection was associated with
significant increase in mean latency time on hot plate
throughout different time intervals with all three doses
(Figure 2A and B). However, the maximum increase in
latency time (P<0.001) in response to heat stimuli was
observed with the dose 3 mg/kg and 10 mg/kg at 90
minutes interval (19.83±2.2 s; 18.33±1.6 s) and 150
minutes interval (14.50±1.3 s; 14.33±0.3 s) respec
tively (Figure 2A). Similarly, for compound 1d all
three doses (1, 3, and 10 mg/kg) also reduced heat
hypersensitivity response and increased the latency
time on a hot plate significantly at 90 minutes interval
(17.83±2.9 s; 17.16±0.4 s, 18.50±0.4 s) and at 150
minutes interval (15.16±1.6 s; 16.66±0.6 s; 19.16±0.9
s) (Figure 2B). Finally intraperitoneal injection of rosi
glitazone (3 mg/kg) increased the latency time of paw
on hot plate starting from 12±1.12 s (*P<0.05) at 60
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Effect of Thiazolidine Derivatives on
Carrageenan-Induced Thermal
Hyperalgesia in Female Mice

Figure 2 Effects of thiazolidine derivatives on carrageenan-induced thermal hyperalge
sia. Adult male mice (n=6 each group) received intra-plantar injection of carrageenan 30
minutes after an intraperitoneal dose of saline, vehicle (5% ethanol, negative control in
case of compound 1b) and (3% DMSO and 1.5% tween-80 negative control in case of
compound 1d), rosiglitazone (3 mg/kg) as positive control; (A) 1b (1, 3, 10 mg/kg) or (B)
1d (1, 3, 10 mg/kg). Thermal pain sensitivity was measured prior to drug administration
(naive baseline), and at 30, 60, 90, 120, and at 150 minute interval after carrageenan
injection by using hotplate assay (54°C±1). Results were analyzed by two-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean±SEM. *P<0.05, **P<0.01,
***P<0.001. ###Denotes comparison between normal control vs negative control.

minutes, 14.33 ± 1.05 s (***P<0.001) at 90 minutes,
12.66±1.33 s (*P<0.05) after 120 minutse and 11.50
±1.28 s (*P<0.05) after 150 minutes, relative to the
negative control group (n=6) (Figure 2A and B). When
tested alone, compound 1b and 1d (1, 3, or 10 mg/kg)
increased latency time on hot plate compared to the
normal control but not to significant extent indicating
1b and 1d possess mild-to-moderate analgesic potential
as well (data not shown).

Drug Design, Development and Therapy 2021:15

Adult female mice (n 6/each group) were given an intraplantar injection of carrageenan (1%) and then tested for
hyperalgesia at 30, 60, 90, 120, and 150 minutes interval.
Reduction in mean withdrawal latencies of the paw in the
negative control group was significant as compared to the
normal control group (Figure 3A and B). Administration of
the compound 1b and 1d 30 minutes before the carrageenan
injection was associated with a significant increase in mean
latency time on hot plate throughout different time intervals
with all three doses (Figure 3A and B). However, the max
imum increase in latency time (P<0.001) in response to heat
stimuli was observed with the dose 3 mg/kg and 10 mg/kg at
90 minutes interval (17.0±0.73 s; 19.33±0.61 s) and 150
minutes interval (15.83±0.9 s; 17.43±0.82 s), respectively
(Figure 3A). Similarly, compound 1d 3 mg/kg and 10 mg/kg
doses also reduced heat hypersensitivity response and
increased the latency time on hot plate significantly at 90
minutes interval (14.83±0.41 s, 16.0±0.89 s) and at 150
minutes interval (14.16±0.47 s; 16.66±0.42 s) (Figure 3B).
Finally intraperitoneal injection of rosiglitazone (3 mg/kg)
increased the latency time of paw on hot plate starting at 60
minute (**P<0.01), at 90 minute (***P<0.001), after 120
minute (***P<0.001) and after 150 minute (**P<0.01),
relative to the negative control group (n=6) (Figure 3A
and B). When tested alone, compound 1b and 1d (1, 3, or
10 mg/kg) increased latency time on hot plate compared to
normal control but not to significant extent indicating 1b
and 1d possess mild-to-moderate analgesic potential as well
(data not shown).

Effect of Thiazolidine Derivatives on
Carrageenan-Induced Mechanical
Allodynia in Male Mice
Carrageenan injection into the paw causes an increased
sensitivity to tactile stimuli. The reduction was substantial
in negative control (5% Ethanol for 1b) starting from 30
minutes of intra-plantar injection of carrageenan at 0.250
±0.034 g (*P<0.05) and 0.267±0.021 g (*P<0.05) at 150
minute interval, in comparison to the saline group (n=6)
(Table 1A). Compound 1b and 1d produced anti-allodynic
effects dose dependently. The anti-allodynic effects of
compound 1b 3 mg/kg were more prominent at 90 minute,
0.517±0.054 g (***P<0.001) and then were reduced at 150
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Figure 3 Effects of thiazolidine derivatives on carrageenan-induced thermal hyperalgesia. Adult female mice (n=6 each group) received intra-plantar injection of carrageenan
after 30 minutes of intraperitoneal dose of saline, vehicle (5% ethanol, negative control in case of compound 1b and 3% DMSO and 1.5% tween-80 negative control in case of
compound 1d), rosiglitazone (3 mg/kg) as positive control; (A) 1b (1, 3, 10 mg/kg) or (B) 1d (1, 3, 10 mg/kg). Thermal pain sensitivity was measured prior to drug
administration (naive baseline), and at 30, 60, 90, 120, and at 150 minute interval after carrageenan injection by using hotplate assay (54°C±1). Results were analyzed by twoway ANOVA followed by Tukey’s post hoc test. Data are expressed as mean±SEM. ***P<0.001. ###Normal control vs negative control.

minute, 0.483±0.031 g (*pP<0.05) relative to the negative
control group (two-way ANOVA, n=6) (Table 1A). The
higher dose of 1b 10 mg/kg significantly reduced tactile
allodynia at 90 minutes, 0.533±0.076 g (***P<0.001) and
maintained up to 150 minutes, 0.650±0.022 g
(***P<0.001) relative to the negative control group (two-

374

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

way ANOVA, n=6) (Table 1A). Similarly, compound 1d 3
mg/kg reduced tactile allodynia significantly at 120 min
ute, 0.500±0.045 g (***P<0.001) and at 150 minute, 0.567
±0.033 g (***P<0.001) as compared to the negative con
trol group (two-way ANOVA, n=6). The higher dose of 1d
10 mg/kg produced the significant anti-allodynic effect at
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Table 1 Effect of Thiazolidine Derivatives on Carrageenan-Induced Mechanical Allodynia. Adult Male Mice (n=6 Each Group), Received
Intra-Plantar Injection of Carrageenan After 30 Minutes After Intraperitoneal Dose of Saline, Vehicle (5% Ethanol, Negative Control in Case
of Compound 1b) and (3% DMSO and 1.5% Tween-80 Negative Control in Case of Compound 1d), Rosiglitazone (3 mg/kg) as Positive
Control; (A) 1b (1, 3, 10 mg/kg) or (B) 1d (1, 3, 10 mg/kg). Mechanical Allodynia Was Measured Prior to Drug Administration (Naïve
Baseline), and at 30, 60, 90, 120, and at 150 Minute Interval After Carrageenan Injection by Using Von Frey Filaments. Results Were Analyzed
by Two-Way ANOVA Followed by Tuckey’s Post Hoc Test. Data are Expressed as Mean±SEM.
A
Mean Paw Withdrawal Latency (Mechanical Allodynia)
Time Duration (minutes)

Normal Control

Negative Control

Positive Control

Compound 1b

Compound 1b

Compound 1b

(1 mg/kg)

(3 mg/kg)

(10 mg/kg)

Zero time

1.920±0.03

1.96±0.040

1.90±0.10

1.960±0.04

2±0.01

1.880±0.05

30

1.307±0.09

0.25#±0.03

0.517* ±0.05

0.383±0.04

0.433±0.07

0.483**±0.07

60

1.170±0.17

0.33#±0.06

0.517 ±0.05

0.403±0.07

0.550*±0.06

0.483*±0.03

90

1.263±0.11

0.21#±0.01

0.583***±0.06

0.417*±0.04

0.517***±0.05

0.533***0.07

120

1.440±0.18

0.21#±0.01

0.583***±0.04

0.467*±0.04

0.450**±0.05

0.617*** ±0.04

150

1.560±0.14

0.26#±0.02

0.533**±0.04

0.50*±0.06

0.483*±0.03

0.650***±0.02

B
Mean Paw Withdrawal Latency (Mechanical Allodynia)
Time Duration (minutes)

Normal Control

Negative Control

Positive Control

Compound 1d

Compound 1d

Compound 1d

(1 mg/kg)

(3 mg/kg)

(10 mg/kg)

Zero time

1.90±0.05

1.960±0.04

1.90±0.1

1.960±0.04

1.960±0.04

1.880±0.05

30

1.313±0.09

0.250#±0.02

0.517±0.05

0.317±0.01

0.483±0.05

0.553**±0.04

60

1.256±0.16

0.333#±0.04

0.517±0.05

0.383±0.04

0.450±0.06

0.567*±0.04

90

1.297±0.11

0.217#±0.04

0.583***±0.06

0.367*± 0.03

0.433**±0.06

0.650***±0.02

120

1.447±0.17

0.207#±0.03

0.583***±0.04

0.383*±0.01

0.500***±0.04

0.567***±0.04

150

1.600±0.12

0.230#±0.03

0.533***±0.04

0.433*± 0.03

0.567***±0.03

0.660***±0.02

#

Notes: *P<0.05, **P<0.01, ***P<0.001. Denotes Comparison Between Normal Control vs Negative Control.

90 minute, 0.650±0.022 g (***P<0.001), at 120 minute,
0.567±0.042 g (***P<0.001), and at 150 minute intervals,
0.650±0.022 g (***P<0.001) (Table 1B). Injection of rosi
glitazone (3 mg/kg) shows a significant reduction in tactile
allodynia with 0.583±0.060 g (***P<0.001) at 90 minute,
and 0.533±0.042 g (***PP<0.001) at 150 minutes after
carrageenan injection as compared to the negative control
group (n=6) (Table 1A and B). These data indicate that
administration of thiazolidine derivatives in higher doses
attenuated the development of allodynia produced due to
carrageenan administration.

Effect of Thiazolidine Derivatives on
Carrageenan-Induced Mechanical
Allodynia in Female Mice
Carrageenan injection into the paw causes an increased
sensitivity to tactile stimuli. The reduction was substantial
in negative control (5% ethanol for 1b) starting at 30
minutes (*P<0.05) of intra-plantar injection of carragee
nan and gradually reduced until the 150 minute interval

Drug Design, Development and Therapy 2021:15

(***P<0.05), in comparison to the normal control group
(n=6) (Table 2A). Compound 1b and 1d produced antiallodynic effects dose dependently. At mg/kg compound
1b showed significant anti-allodynic effects at all the inter
vals starting at 60 minute (***P<0.001) up-to 150 minute
(***P<0.001) relative to the negative control group (twoway ANOVA, n=6) (Table 2A). The higher dose of 1b 10
mg/kg significantly reduced tactile allodynia at all the
intervals starting from 90 minutes (***P<0.001) and main
tained up-to 150 minutes (***P<0.001) relative to the
negative control group (two-way ANOVA, n=6)
(Table 2A). Similarly, compound 1d 3 mg/kg reduced
tactile
allodynia
significantly
at
90
minutes
(***P<0.001), at 120 minutes (***P<0.001), and at 150
minutes (***P<0.001) as compared to the negative control
group (two-way ANOVA, n=6) (Table 2B). The higher
dose of 1d 10 mg/kg produced the significant anti-allody
nic effect at 90 minute (***P<0.001), at 120 minute
(***P<0.001), and at 150 minute interval (***P<0.001)
(Table 2B) as compared to the negative control group.
Injection of Rosiglitazone (3 mg/kg) shows a significant
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Table 2 Effect of Thiazolidine Derivatives on Carrageenan-Induced Mechanical Allodynia. Adult Female Mice (n=6 Each Group)
Received Intra-Plantar Injection of Carrageenan After 30 Minutes of Intraperitoneal Dose of Saline, Vehicle (5% Ethanol, Negative
Control in Case of Compound 1b and 3% DMSO and 1.5% Tween-80 Negative Control in Case of Compound 1d), Rosiglitazone (3
mg/kg) as Positive Control; (A) 1b (1, 3, 10 mg/kg) or (B) 1d (1, 3, 10 mg/kg). Mechanical Allodynia Was Measured Prior to Drug
Administration (Naïve Baseline), and at 30, 60, 90, 120, and at 150 Minute Intervals After Carrageenan Injection by Using Von Frey
Filaments. Results Were Analyzed by Two-Way ANOVA Followed by Tukey’s Post Hoc Test. Data are Expressed as Mean±SEM
A
Mean Paw Withdrawal Latency (Mechanical Allodynia)
Time Duration
(minutes)

Normal
Control

Negative
Control

Positive
Control

Compound 1b
(1 mg/kg)

Compound 1b
(3 mg/kg)

Compound 1b
(10 mg/kg)

Zero time

1.880±0.04

1.96±0.04

1.80±0.1

1.92±0.04

1.92±0.04

1.92±0.05

30

1.333±0.09

0.28#±0.03

0.64***±0.09

0.43±0.05

0.53±0.04

0.64**±0.05

60
90

1.323±0.18
1.303±0.11

0.36#±0.06
0.21#±0.01

0.55*±0.04
0.68***±0.03

0.50±0.05
0.41±0.04

0.58*±0.04
0.53**±0.03

0.56±0.03
0.63***±0.06

120

1.493±0.16

0.23#±0.01

0.61***±0.06

0.56**±0.08

0.53**±0.03

0.63***±0.05

150

1.660±0.12

0.23#±0.02

0.63***±0.06

0.53*±0.05

0.50**±0.03

0.68***±0.04

B
Mean Paw Withdrawal Latency (Mechanical Allodynia)
Time Duration
(minutes)

Normal
Control

Negative
Control

Positive
Control

Compound 1d
(1 mg/kg)

Compound 1d
(3 mg/kg)

Compound 1d
(10 mg/kg)

Zero time
30

1.880±0.05
1.347±0.08

1.96±0.040
0.35#±0.02

1.92±0.5
0.66***±0.09

1.88±0.05
0.40±0.04

1.96±0.04
0.55*±0.05

1.96±0.05
0.58*±0.04

60

1.377±0.16

0.38#±0.04

0.62*±0.07

0.46±0.03

0.56±0.06

0.60*±0.02

90
120

1.367±0.08
1.513±0.15

0.26#±0.02
0.20#±0.03

0.66***±0.03
0.69***±0.05

0.46*±0.04
0.45**±0.03

0.56**±0.04
0.6***±0.02

0.73***±0.02
0.77***±0.05

150

1.627±0.13

0.23#±0.03

0.69***±0.04

0.48**±0.04

0.65***±0.02

0.79***±0.07

#

Notes: *P<0.05, **P<0.01, ***P<0.001. Denotes Comparison Between Normal Control vs Negative Control.

reduction in tactile allodynia at all intervals as compared
to the negative control group (n=6) (Table 2A and B).
These data indicate that anti-allodynic effects of thiazoli
dine derivatives were increased at higher doses.

Effect of Thiazolidine Derivatives on
Rota-Rod Test

Effect of Thiazolidine Derivatives on IL-1β
Production in the Spinal Cord in
Response to Carrageenan-Induced
Inflammation in Male Mice

Administration of diazepam (2 mg/kg) affect the motor
coordination in mice and significantly reduced the time of
permeance on bar after 1 hour (P<0.001) and 3 hours
(P<0.001) in this test. Whereas the administration of 3 mg/
kg and 10 mg/kg doses of compound 1b did not affect the
motor coordination in mice and no significant change in the
time of permanence on bar was observed at 1 hour and 3
hours after the administration of compound as compared to
control (Figure 4A). Similarly, the 3 mg/kg and 10 mg/kg
dose of compound 1d did not affect the motor coordination in
mice and no change was observed in the time of permanence
at 1 hour and at 3 hours after administration of 1d as

Peripheral inflammation in the negative control group caused
a significant increase in the production of IL-1β in the spinal
cord of mice as compared to the normal control (Figure 5A
and B). Compound 1b (10 mg/kg) caused a significant reduc
tion in IL-1β production (**P<0.01) compared to the mice
treated in the negative control group (Figure 5A). Similarly,
injection of 1d (10 mg/kg) also reduced IL-1β production
significantly (**P<0.01) in comparison to negative control
(Figure 5B). Rosiglitazone administration also caused a
decrease in IL-1β production significantly (**P<0.01) in
comparison to the negative control treatment group
(Figure 5A and B).
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compared to control (Figure 4B). These data suggest that
the compounds lack effect on locomotor activity.
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Figure 4 Effect of thiazolidine derivatives on time of permanence in Rota-rod test. Adult male mice (n=6 each group) received intraperitoneal injection of diazepam (2 mg/
kg) dissolved in vehicle (5% ethanol, in case of compound 1b and 3% DMSO and 1.5% tween-80 in case of compound 1d), (A) Compound 1b (3, 10 mg/kg) or (B) Compound
1d (3, 10 mg/kg). Time of permanence was measured prior to drug administration at 0 hour, and at 1 and 3 hours after drug administration by using Rota-Rod apparatus.
Results were analyzed by two-way ANOVA followed by Tuckey’s post-hoc test. Data are expressed as mean±SEM. #Normal control vs diazepam.

Effect of Thiazolidine Derivatives on IL-1β
Production in the Spinal Cord in
Response to Carrageenan-Induced
Inflammation in Female Mice
Carrageenan and vehicle administered animal groups exhibited
a significant increase in the production of IL-1β in the spinal
cord of mice (Figure 6A and B). Compound 1b (10 mg/kg)
caused a significant reduction in IL-1β production (**P<0.01)
compared to the mice treated in the negative control group
(Figure 6A). Similarly, the compound 1d (10 mg/kg) also

Drug Design, Development and Therapy 2021:15

reduced IL-1β production, (**P<0.01) in comparison to the
negative control group (Figure 6B). Rosiglitazone administra
tion also caused a significant decrease in the IL-1β production
(**P<0.01) in comparison to the negative control treatment
group (Figure 6A and B).

Antioxidant Effect
In the DPPH assay, the presence of free radicals decolorize
DPPH, which is a stable free radical. Due to the change of
color from purple to yellow the absorbance decreases as
antioxidants scavenge the radical due to the donation of
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Figure 5 A. Effect of thiazolidine derivative, 1bon IL-1β production in the spinal cord in response to carrageenan-induced inflammation in male mice. B. Effect of thiazolidine
derivative 1d on IL-1β production in the spinal cord in response to carrageenan-induced inflammation in male mice. Animals were sacrificed; spinal cords were isolated and
stored at −80ºC. The spinal cord was homogenized as described in the method section and the IL-1β levels were measured by ELISA assay. **P<0.01. Analyzed by one-way
ANOVA followed by Tukey’s post hoc test. ###Normal control vs negative control.

hydrogen to make a stable DPPH-H molecule. Table 3
shows the free radical scavenging activity of the com
pound 1b, 1d, and ascorbic acid. IC50 for each of the 1b,
1d, and ascorbic acid was calculated. 1b with IC50 of 604
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μg/mL showed a radical scavenging effect. Similarly, the
antioxidant activity of 1d was observed with IC50 of 537
μg/mL. Meanwhile with the IC50 value of 244 μg/mL
ascorbic acid exhibited the antioxidant activity.
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Figure 6 A. Effect of thiazolidine derivative, 1b, on IL-1β production in the spinal cord in response to carrageenan-induced inflammation in female mice. B. Effect of
thiazolidine derivative, 1d on IL-1β production in the spinal cord in response to carrageenan-induced inflammation in female mice.Animals were sacrificed; spinal cords were
isolated and stored at −80ºC. The spinal cord was homogenized as described in the method section and the IL-1β levels were measured by ELISA assay. *P<0.05, **P<0.01.
Analyzed by one-way ANOVA followed by Tukey’s post hoc test. ###Normal control vs negative control.

Acute and Sub-Acute Toxicity in Animal
Model

of thiazolidine derivatives on the liver injury, biomarkers of

In acute toxicity study, all mice survived and no change in
animal’s behavior was observed after 24 hours of 1b and 1d
administration. In sub-acute toxicity, to investigate the effects

serum. The liver plays a major role in the metabolic processes

Drug Design, Development and Therapy 2021:15

liver injury such as ALP, AST, and ALT were measured in the
of most substances. Thus, any disturbance in the liver could be
reflected by the level of the biochemical parameters present in
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Table 3 Evaluation of the Antioxidant Activity by DPPH Method (Mean±SEM)
Concentration(μg/mL)

1b+DPPH

1d+DPPH

Ascorbic Acid

1
3

7.508672479±0.52
8.176514163±0.27

4.434±0.16
19.939±0.22

2.164±0.17
4.312±0.35

10

13.96236335±0.45

38.034±0.08

4.234±0.31

100
300

38.48731793±0.35
44.74783508±0.47

38.704±0.53
41.941±0.02

15.953±0.62
64.181±0.12

700

53.99150205±0.42

56.963±0.24

92.223±0.02

1000
Blank (negative control)

57.19600295±0.99
3.199

68.861±0.35
2.771

93.290±0.07
3.341

IC50

604 μg/mL

537 μg/mL

241 μg/mL

the blood. During the damage to the liver cells and tissues, the
activities of these enzymes are usually elevated. No significant
change in the serum levels of liver injury biomarkers was
observed after single day treatment and after 14 days of con
secutive administration of the compounds (Table 4). Possible
kidney damage with short-term administration (1 day) and
long-term administration of the compounds was evaluated by
measuring creatinine levels in the serum. No significant
change in the creatinine level was observed after both shortterm and long-term administration of the compounds
(Table 4).

Discussion
The current study reveals that administration of thiazoli
dine derivatives, 1b and 1d, decreased carrageenaninduced thermal hyperalgesia and mechanical allodynia
and reduced proinflammatory cytokines, IL-1β expression
in both male and female mice groups. This indicates that
thiazolidine derivatives reduce neuroinflammatory painlike symptoms involving decreased production of IL-1β.
The subcutaneous injection of carrageenan produces
local inflammation. The sensitivity to noxious stimuli

(hyperalgesia) increases in peripheral tissue injury (inflam
mation) and also induces a sensation of pain in reaction to
light-touch (allodynia). In the central nervous system
enhanced responsiveness of nociceptive neurons to the
normal afferent input is called central sensitization and it
is considered a mechanism which is responsible for hyper
algesia and allodynia.40,41 Glial cells in the spinal dorsal
horn are activated as a result of peripheral nerve injury and
peripheral tissue injury. Activated glial cells in the spinal
dorsal horn are involved in transmission of spinal nocicep
tion and central sensitization.42 Activated glial cells
release multiple proinflammatory mediators in the spinal
cord.43 Pro-inflammatory mediators such as IL-1β rise in
the spinal cord in response to nerve damage or peripheral
inflammation.44 The excitability of primary neurons in
response to external stimuli is increased by spinal proin
flammatory mediators.40,45
Peroxisome proliferator-activated receptors act as ligandactivated transcription factors. These receptors belong to the
nuclear hormone receptor superfamily. Three types of PPAR
α, β, and γ have been identified. These receptors play a very
important role in the production of immunomodulatory
cytokines.46 Some previous studies have shown that PPARγ

Table 4 Levels of the Liver and Kidney Injury Biomarkers Observed in Male and Female Mice After the Short-Term (1 Day) and LongTerm (14 Days) Administration of the Thiazolidine Derivates. The Values are Expressed as Mean±SD of Six Animals
1 Day

Control

Compound 1b

Compound 1d
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14 Days

ALP (U/L)

AST (U/L)

ALT (U/L)

Creatinine (µmol/L

ALP (U/L)

AST (U/L)

ALT (U/L)

Creatinine (µmol/L)

Male

10.67±1.20

42.34±1.22

12.21±0.8

17.64±0.54

11.57±1.34

46.15±1.11

13.81±1.24

15.74±0.46

Female

11.43±1.22

50.5±1.44

14.20±0.9

16.12±0.81

13.23±2.1

54.6±0.74

15.50±0.29

17.32±1.31

Male

10.43±1.22

40.21±1.20

11.47±0.7

17.23±0.77

14.33±1.05

53.13±1.35

13.86±0.44

19.36±1.42

Female

13.21±1.22

51.14±1.6

12.63±1.4

17.86±0.64

15.31±0.88

55.64±1.33

13.88±0.41

19.42±1.67

Male

11.3±0.0.99

43.52±1.24

12.5±0.8

15.17±1.22

13.45±0.1.35

54.11±2.23

14.61±0.89

20.42±1.0

Female

12.5±0.88

52.41±2.2

14.83±0.6

16.82±1.06

14.53±1.45

54.75±1.12

15.73±0.48

19.71±1.5
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ligands exert additional CNS actions on nociceptive signal
ing pathways, likely by their action at PPAR receptors in the
brain.47 The involvement of PPARγ in inflammatory pro
cesses was first suggested by the antagonism between the
activities of proinflammatory cytokines and PPARγ.48 It was
reported that mice deficient of PPARγ receptor had a greater
inflammatory response which was induced by both arachi
donic acid and leukotriene B4. PPARγ ligands also lessened
the behavioral signs of inflammatory pain in rats which was
confirmed by a study on PPAR-α deletion-mutant mice.49,50
In a study conducted, it was observed that repeated thiazoli
dine derivatives doses cause reduction of inflammatory pain
via action on PPARγ receptors.51 Thiazolidine derivatives
agonize PPARγ in the spinal cord and reduce inflammatory
cytokines.52–55
Thiazolidine derivatives, 1b, and 1d, are promising
anti-inflammatory candidates and possess possible thera
peutic potential for the management of inflammatory pain.
In this study, the thiazolidine derivatives exerted pro
nounced anti-inflammatory effects by reducing the levels
of proinflammatory cytokines such as IL-1β. It was also
suggested that thiazolidine derivatives might exert these
effects of reducing levels of IL-1β by acting on PPARs.15
1b (3 or 10 mg/kg) increased the duration of reaction to
the hot plate test. Compound 1b also causes an increase in
the withdrawal threshold of the mice paw at doses (3 or
10 mg/kg) in Von Frey filament test. Similarly, the time of
reaction to the hot plate was increased by 1d (1, 3, or
10 mg/kg) and a greater paw withdrawal threshold at a
dose of 10 mg/kg. All these results show that both com
pounds are more successful at higher doses in producing
desired effects. It was also observed that the anti-nocicep
tive activity of these compounds could not be due to their
sedative effect, because the results of the Rota-rod test did
to exhibit any motor coordination defects in mice admi
nistered 1b and 1d which implies that compounds do not
have any sedative or motor coordination effects.
Thiazolidine derivatives 1b or 1d (1, 3, or 10 mg/kg)
dose-dependently reduced IL-1β production in the lumbar
spinal cord of the mice in response to carrageenan-induced
peripheral inflammation in exhibiting a reduction in proin
flammatory cytokines contents. In a similar study, thiazo
lidine derivatives exhibited promising anti-inflammatory,
antinociceptive activities which are related to their ability
to inhibit IL-1β production. Inflammation is the veritable
cause of pain, and inhibitors of inflammatory mediators
like IL-1β have shown remarkable analgesic effects.
However, when tested alone, compound 1b and 1d (1, 3,

Drug Design, Development and Therapy 2021:15

Malik et al

or 10 mg/kg) increased latency time on hot plate compared
to normal control but not to a significant extent, indicating
1b and 1d, in addition to anti-hyperalgesic effect, possess
mild-to-moderate analgesic potential (data not shown).
All these data taken together propose that thiazolidine
derivatives 1b and 1d administration may reduce the neu
roinflammatory consequence of inflammatory pain as it
reduces the IL-1β up-regulation in the lumber spinal cord
region of mice in which inflammatory pain was induced by
carrageenan, which indicates that pro-inflammatory con
sequences of peripheral inflammation can be reduced by
administration of thiazolidine derivatives.
A close relationship between oxidative stress and
inflammation has been reported so that oxidative stress
following inflammation can induce more inflammation
through different pathways and vice versa.21,56,57
Previous studies have shown that cytokines alter the
redox equilibrium by affecting GSH/GSSG shuttling and
recycling.58,59 It has been observed that antioxidants effec
tively suppressed the expression of proinflammatory cyto
kines, such as IL-1β as well as oxidants induced by
ischemia injury.60 It has been reported that IL-1β is an
effective mediator of spinal cord inflammation and oxida
tive stress, and blocking IL-1β could be a potential therapy
for pain hypersensitivity development.61 Studies have
reported that reducing the levels of oxidative stress pro
ducts in the spinal cord reduced hyperalgesia and
allodynia.19,62–64 The in vitro antioxidant activities of the
thiazolidine derivatives were also performed by DPPH
free radical scavenging assay. Antioxidants have a hydro
gen donating ability, hence provide DPPH free radical
scavenging. The antioxidant potential of both compounds
was promising on the basis of their calculated IC50 value.
The acute toxicity showed the safety of thiazolidine
derivatives, as no mortality or other significant gross beha
vioral changes were observed at 1,000 mg/kg. Therefore,
LD50 of the compounds could be greater than 1,000 mg/
kg. In a sub-acute toxicity study, no significant alleviation
in the serum levels of liver injury biomarkers ALP, AST,
and ALT were observed after 14 days of the treatment with
thiazolidine derivatives 1b and 1d. ALP is a known marker
enzyme for plasma membrane and endoplasmic reticulum
of the tissue. It is an indicator of acute liver damage. ALT
has its highest concentration in the liver, with kidney and
skeletal muscles having lesser activity of these enzymes. It
is also an acute liver damage indicator. Creatinine levels in
the serum after 14 days of the treatment with thiazolidine
derivatives also did not change significantly, suggesting
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that thiazolidine derivatives 1b and 1d are not toxic to the
kidney cells. Studies previously conducted on acute toxi
city (LD50) of thiazolidine derivatives in a range of oral
doses 25, 50, 100, 250, 500, and 1,000 mg/kg did not show
any toxicity. Similarly, in another study thiazolidine deri
vatives were shown to be safe according to the parameters
of mutagenicity, teratogenicity, carcinogenicity, and repro
ductive toxicity.65

Conclusion
In conclusion, the present study clearly demonstrates that
thiazolidine derivatives: [2-(2 hydroxyphenyl)-1,3-thiazoli
din-4-yl](morpholin-4-yl)methanone, and 2-hydroxy-4-{[2(2-hydroxyphenyl)-1,3-thiazolidine-4-carbonyl]amino}ben
zoic acid exhibit analgesic effects with 1-d having pro
nounced activity than 1-b. Their possible mechanism is due
to PPARγ agonist activity, which indicates their therapeutic
potential in inflammatory pain. The analgesic effects and
ability to suppress IL-1β expression in spinal cord increased
with higher doses. However, it is suggested that further
research on underlying pathways of inflammatory pain is
required that would improve the clinical management of
inflammatory pain.
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